Comprehensive Pan-cancer Analysis and Experimental Verification of EGLN Family: Potential Biomarkers in Cervical Cancer.

IF 2.3 4区医学 Q3 ONCOLOGY

Current cancer drug targets Pub Date : 2025-06-03 DOI:10.2174/0115680096362252250527060004

Dongli Zhang, Ruifang Fu, Guixia Sun, Junfang Yan, Xiaofeng Yang

{"title":"Comprehensive Pan-cancer Analysis and Experimental Verification of EGLN Family: Potential Biomarkers in Cervical Cancer.","authors":"Dongli Zhang, Ruifang Fu, Guixia Sun, Junfang Yan, Xiaofeng Yang","doi":"10.2174/0115680096362252250527060004","DOIUrl":null,"url":null,"abstract":"Background: Hypoxia plays a crucial role in malignant tumor formation, primarily mediated by hypoxia-inducible factors (HIFs). Despite extensive research, the complexities and prognostic implications of the EGLN gene family (EGLN1, EGLN2, EGLN3) in cancers remain unclear.Methods: Utilizing public databases (TCGA, GTEx, TARGET, GEO) and bioinformatics tools, a comprehensive analysis of EGLN genes across various cancer types was conducted. Gene ex-pression, mutation data, stemness scores, and clinical information were integrated to evaluate the mutation landscape, expression levels, and prognostic values of EGLNs. Enrichment and pathway analyses explored EGLN-associated biological processes and functional networks. ssGSEA con-structed EGLN scores for prognostic evaluation. Colocalization analysis combined eQTL and GWAS data to investigate genetic variations in cervical cancer. Immunohistochemistry validated EGLN expression in cervical cancer tissues.Results: EGLN genes showed differential expression across cancer types. EGLN1 overexpres-sion was associated with worse survival in cervical squamous cell carcinoma (CESC), pancreatic adenocarcinoma (PAAD), and neuroblastoma (NB), while EGLN3 was linked to poor survival in CESC, lung adenocarcinoma (LUAD), and kidney cancers. EGLNs also demonstrated varied roles in modulating tumor immune activity and heterogeneity.Conclusion: This study provides new insights into EGLN biology and identifies EGLN1 as a potential biomarker for cervical cancer.","PeriodicalId":10816,"journal":{"name":"Current cancer drug targets","volume":" ","pages":""},"PeriodicalIF":2.3000,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current cancer drug targets","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0115680096362252250527060004","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Hypoxia plays a crucial role in malignant tumor formation, primarily mediated by hypoxia-inducible factors (HIFs). Despite extensive research, the complexities and prognostic implications of the EGLN gene family (EGLN1, EGLN2, EGLN3) in cancers remain unclear.

Methods: Utilizing public databases (TCGA, GTEx, TARGET, GEO) and bioinformatics tools, a comprehensive analysis of EGLN genes across various cancer types was conducted. Gene ex-pression, mutation data, stemness scores, and clinical information were integrated to evaluate the mutation landscape, expression levels, and prognostic values of EGLNs. Enrichment and pathway analyses explored EGLN-associated biological processes and functional networks. ssGSEA con-structed EGLN scores for prognostic evaluation. Colocalization analysis combined eQTL and GWAS data to investigate genetic variations in cervical cancer. Immunohistochemistry validated EGLN expression in cervical cancer tissues.

Results: EGLN genes showed differential expression across cancer types. EGLN1 overexpres-sion was associated with worse survival in cervical squamous cell carcinoma (CESC), pancreatic adenocarcinoma (PAAD), and neuroblastoma (NB), while EGLN3 was linked to poor survival in CESC, lung adenocarcinoma (LUAD), and kidney cancers. EGLNs also demonstrated varied roles in modulating tumor immune activity and heterogeneity.

Conclusion: This study provides new insights into EGLN biology and identifies EGLN1 as a potential biomarker for cervical cancer.

查看原文本刊更多论文

EGLN家族：宫颈癌潜在生物标志物的泛癌综合分析与实验验证

背景：缺氧在恶性肿瘤的形成中起着至关重要的作用，主要由缺氧诱导因子（hif）介导。尽管进行了广泛的研究，但EGLN基因家族（EGLN1, EGLN2, EGLN3）在癌症中的复杂性和预后意义仍不清楚。方法：利用公共数据库（TCGA、GTEx、TARGET、GEO）和生物信息学工具，对不同肿瘤类型的EGLN基因进行综合分析。整合基因表达、突变数据、stemness评分和临床信息来评估EGLNs的突变情况、表达水平和预后价值。富集和通路分析探讨了egln相关的生物学过程和功能网络。ssGSEA构建EGLN评分用于预后评估。结合eQTL和GWAS数据的共定位分析研究宫颈癌的遗传变异。免疫组化证实EGLN在宫颈癌组织中的表达。结果：EGLN基因在不同肿瘤类型中表达存在差异。EGLN1过表达与宫颈鳞状细胞癌（CESC）、胰腺腺癌（PAAD）和神经母细胞瘤（NB）的较差生存率相关，而EGLN3与CESC、肺腺癌（LUAD）和肾癌的较差生存率相关。EGLNs在调节肿瘤免疫活性和异质性方面也表现出不同的作用。结论：本研究为EGLN生物学提供了新的见解，并确定EGLN1是宫颈癌的潜在生物标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current cancer drug targets 医学-肿瘤学

CiteScore

5.40

自引率

0.00%

发文量

105

审稿时长

1 months

期刊介绍： Current Cancer Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular drug targets involved in cancer, e.g. disease specific proteins, receptors, enzymes and genes. Current Cancer Drug Targets publishes original research articles, letters, reviews / mini-reviews, drug clinical trial studies and guest edited thematic issues written by leaders in the field covering a range of current topics on drug targets involved in cancer. As the discovery, identification, characterization and validation of novel human drug targets for anti-cancer drug discovery continues to grow; this journal has become essential reading for all pharmaceutical scientists involved in drug discovery and development.